Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRN help wanted

This article was originally published in The Tan Sheet

Executive Summary

The trade association has formed a committee to find a replacement for current President Annette Dickinson, PhD, who announced her tentative retirement after 31 years with CRN in June (1"The Tan Sheet" June 24, 2004, p. 14). Dickinson plans to retire in spring 2005, but could step down earlier if necessary "to accommodate a candidate who prefers to start sooner." The committee is comprised of nine CRN board members, including Natural Alternatives Chairman Mark LeDoux, Wyeth Consumer Healthcare Senior VP Andrew Davis, NBTY CFO Harvey Kamil, John Vernardos of Herbalife and Tom Zimmerman of Pharmavite...

You may also be interested in...



CRN’s Dickinson Concludes 31-Year Tenure

The Council for Responsible Nutrition will convene a search committee within the next few weeks to hire a successor for CRN President Annette Dickinson, PhD

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel